Pfizer has started a study of its COVID-19 pill in children who have COVID-19 and are designated as being at high risk for experiencing severe symptoms.
The phase 2/phase 3 study has about 140 participants between the ages of 6 and 17.
Pfizer Begins Study of COVID-19 Pill in High-Risk Children
Save
A box of Paxlovid, Pfizer's COVID-19 pill, is seen in a file image. Jennifer Lorenzini/Reuters
Updated:
